Virginia's Department of Medical Assistance Services
Pharmacy and Therapeutics Committee Meeting
600 East Broad Street –1st Floor Conference Rooms
Richmond, Virginia 23219
Thursday, January 21, 2027 - 12:00 p.m.

Welcome and Call to Order	**JoeMichael Fusco, PharmD, Director of Pharmacy Programs and Strategy, Chair**
Comments from DMAS' Director	**Steve Ford, Medicaid Director**
Introductions and Housekeeping	**Matt Estes, PharmD (Prime Therapeutics)**
Drug Utilization Review (DUR) Board Update	**Rachel Cain, PharmD**
Approval of Minutes from October 15, 2026	**P&T Committee Members**
Old Business	**P&T Committee Members**
PDL Management	**P&T Committee Members**

Off Cycle Class Review
- Lipotropics, Other

PDL Quarter 1 – New Drug Review (Therapeutic Class)

PDL Quarter 1 – Annual Class Review: Classes With Updates

Blood Modifiers
- Antihyperuricemics
- Erythropoiesis Stimulating Proteins
- Colony Stimulating Factors (Closed Class)

Central Nervous System
- CNS Stimulants and related agents (Closed Class)
- Alzheimer's Agents (Cholinesterase Inhibitors & NMDA Receptor Antagonist)
- Multiple Sclerosis Agents (Closed Class)
- Neuropathic Pain and Select Agents
- Duchenne Muscular Dystrophy (Closed Class)
- Skeletal Muscle Relaxants
- Smoking Cessation Agents

Endocrine and Metabolic Agents
- Androgenic Agents
- Bone Resorption Suppression and Related Agents (includes bisphosphonates, calcitonin and others)
- Estrogens (vaginal)
- Hypoglycemics: Alpha-Glucosidase Inhibitors

DRAFT

- Hypoglycemics: Incretin-Mimetics (includes DPPIV & combination) (Closed Class)
- Hypoglycemics: Insulins
- Hypoglycemics: Meglitinides
- Hypoglycemics: Metformin
- Hypoglycemics: Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor (Closed Class)
- Hypoglycemics: Sulfonylureas
- Hypoglycemics: Thiazolidinediones
- Pancreatic Enzymes
- Progestational Agent (Closed Class)
- Weight Management Agents (Closed Class)

Immunological Agents

- Cytokine & CAM Antagonists with Related Agents (all indications: Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA), Ankylosing Spondylitis (AS), Plaque Psoriasis, Psoriatic Arthritis (PsA), Crohn's Disease (CD), Ulcerative Colitis, Cryopyrin-Associated Periodic Syndromes (CAPS) (Closed Class)
- Methotrexate (Closed Class)

Confidential Meeting (Pricing Information Discussion) **P&T Committee Members & DMAS Staff**

PDL Recommendations and Vote **P&T Committee Members**

Criteria Discussion* **P&T Committee Members**

Next Meeting - tentatively scheduled for April 15, 2027.

**Criteria discussions will be held for classes only if deemed PDL eligible by the P&T Committee during Drug Class Discussions.*

Oral Presentations: The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL off cycle drugs in classes in which are scheduled for review at the January meeting and new PDL Quarter 1 drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- PDL Quarter 1 Annual Reviews – January 2026 to present
- New Drugs in off cycle Drug Classes – January 2025 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information. **Speakers must receive a confirmation number to verify the presentation is scheduled.**

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to pdlinput@dmas.virginia.gov and matt.estes@primetherapeutics.com **by 5 p.m. EST on Friday, December 11, 2026.**

DRAFT

Written information/comments: The P&T Committee will also accept written comments for consideration. Please send statements to pdlinput@dmas.virginia.gov **by 5 p.m. EST on Friday December 11, 2026.**

DRAFT